Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Conference Call January 23, 2024 8:30 AM ET
Company Participants
Jessica Moore - VP, IR
Joaquin Duato - Chairman & CEO
Joseph Wolk - EVP & CFO
Conference Call Participants
Joanne Wuensch - Citibank
Terence Flynn - Morgan Stanley
Lawrence Biegelsen - Wells Fargo
Chris Schott - JPMorgan
Shagun Singh - RBC Capital Markets
Vamil Divan - Guggenheim Securities
Louise Chen - Cantor Fitzgerald
Matt Miksic - Barclays
Geoff Meacham - Bank of America
Danielle Antalffy - UBS
David Risinger - Leerink Partners
Frederick Wise - Stifel
Operator
Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions]
I would now like to turn the conference call over to Johnson & Johnson. You may begin.
Jessica Moore
Good morning. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the fourth quarter and full year 2023 and our financial outlook for 2024.
Joining me on today's call are Joaquin Duato, Chairman and Chief Executive Officer; and Joe Wolk, Executive Vice President, Chief Financial Officer. As a remainder, you can find additional materials including today's presentation and associated schedules on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events using the information available as of the date of this recording, and are subject to certain risk and uncertainties that may cause the company's actual results to differ materially from those projected.
A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2022 Form 10-K, which is available at investor.jnj.com and on the SECs website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.
Moving to today's agenda. Joaquin will open with the few comments on our 2023 performance and key milestones, as well as highlights from our Enterprise Business Review. I will then review the fourth quarter sales and P&L results as well as full year 2023 results for the Enterprise. Joe will then close by sharing an overview of our cash position, capital allocation priorities, and guidance for 2024. The remaining time will be available for your questions. To ensure we provide enough time to address your questions, we anticipate the webcast will last a little over 60 minutes.